ALLSCHWIL/BASEL, SWITZERLAND- 14 June 2017 - Actelion Ltd (SIX: ATLN) today announced changes to its executive team that will take effect upon the settlement of the public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH, for all publicly held shares of Actelion which is expected to occur on 16 June 2017 (Settlement). As previously announced, Jane Griffiths will assume the position as Actelion's Global Head and Otto Schwarz will retire from his position as Chief Operating Officer upon Settlement. Jean-Paul Clozel, CEO, André C. Muller, CFO, and Guy Braunstein, Head of Global Clinical Development, will leave Actelion's...
↧